ALVO Stock Analysis: Alvotech | NASDAQ

Biosimilars, Autoimmune Treatments, Eye Disorder Therapies, Cancer Treatments

Total Rating 14

Safety 37

Buy Signal -0.23

Drug Manufacturers - Specialty & Generic
Industry Rotation: +0.4

Market Cap: 1.50B
Avg Turnover: 3.01M

Risk 3d forecast

Volatility75.3%

VaR 5^th Pctl10.7%

VaR vs Median-9.87%

Reward TTM

Sharpe Ratio-0.28

Rel. Str. IBD68.5

Rel. Str. Peer Group35.3

Character TTM

Beta0.645

Beta Downside0.047

Hurst Exponent0.406

Drawdowns 3y

Max DD82.63%

CAGR/Max DD-0.23

CAGR/Mean DD-0.46

EPS (Earnings per Share)

Last SUE: -0.22
Qual. Beats: 0

Revenue

Rev. CAGR: 115.85%
Rev. Trend: 84.2%

Last SUE: -0.04
Qual. Beats: 0

Warnings

Negative Equity With Losses

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Overextended 1w

Choppy

Tailwinds

Ep Pivot

Seasonality 5.6 years of data

Jan +14.6% 12

Feb +0.1% 9

Mar -6.9% 32

Apr +0.0% 9

May +0.2% 9

Jun -11.8% 34

Jul +0.1% 0

Aug +3.2% 21

Sep -1.0% 0

Oct -0.1% 0

Nov +0.1% 9

Dec +14.0% 34

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ALVO Alvotech

Alvotech is a Luxembourg-based biopharmaceutical company that develops and manufactures biosimilar medicines for the global market, with operations spanning therapeutic areas including autoimmune diseases, eye disorders, bone conditions, and cancer. Its portfolio includes multiple biosimilar candidates targeting major reference biologics such as Humira (AVT02), Stelara (AVT04), Eylea (AVT06), Xgeva/Prolia (AVT03), Simponi (AVT05), Entyvio (AVT16), Xolair (AVT23), and an early-stage candidate referencing Keytruda (AVT33). Founded in 2013, the company listed on NASDAQ in June 2022 and is classified within the biotechnology sub-industry of the healthcare sector.

Unlike generic small-molecule drugs, biosimilars are large-molecule medicines designed to be highly similar to already-approved biologic reference products, requiring extensive clinical comparability studies and specialized manufacturing capabilities. The biosimilar industry has expanded as patents on blockbuster biologics have expired, positioning companies like Alvotech to compete on price in therapeutic categories historically dominated by single-originator products.

Headlines to Watch Out For

FDA approval of Stelara biosimilar AVT04 accelerates commercial revenue ramp
Humira biosimilar AVT02 faces intensifying U.S. pricing competition from multiple entrants
Capital raises and debt refinancing needed to fund ongoing operating cash burn

Piotroski VR-10 (Strict) 1.5

Net Income: -179.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.19 > 0.02 and ΔFCF/TA -9.98 > 1.0
NWC/Revenue: 43.46% < 20% (prev 41.01%; Δ 2.44% < -1%)
CFO/TA -0.13 > 3% & CFO -198.7m > Net Income -179.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.65 > 1.5 & < 3
Outstanding Shares: last quarter (356.8m) vs 12m ago 13.86% < -2%
Gross Margin: 60.45% > 18% (prev 53.68%; Δ 6.77% > 0.5%)
Asset Turnover: 33.01% > 50% (prev 40.21%; Δ -7.20% > 0%)
Interest Coverage Ratio: -0.22 > 6 (EBIT TTM -34.8m / Interest Expense TTM 158.8m)

Altman Z'' -4.47

A: 0.13 (Total Current Assets 545.0m - Total Current Liabilities 331.2m) / Total Assets 1.59b
B: -1.56 (Retained Earnings -2.48b / Total Assets 1.59b)
C: -0.02 (EBIT TTM -34.8m / Avg Total Assets 1.49b)
D: -0.11 (Book Value of Equity -191.5m / Total Liabilities 1.78b)
Altman-Z'' = -4.47 = D

Beneish M -3.41

DSRI: 0.73 (Receivables 115.4m/180.4m, Revenue 492.0m/560.1m)
GMI: 0.89 (GM 53.68% / 60.45%)
AQI: 1.05 (AQ_t 0.33 / AQ_t-1 0.32)
SGI: 0.88 (Revenue 492.0m / 560.1m)
TATA: 0.01 (NI -179.6m - CFO -198.7m) / TA 1.59b)
Beneish M = -3.41 (Cap -4..+1) = AA

What is the price of ALVO shares?

As of August 25, 2026, the stock is trading at USD 5.25 with a total of 3,171,623 shares traded. Over the past week, the price has changed by +35.31%, over one month by +71.57%, over three months by +53.51% and over the past year by -36.90%.

Current recommended Stop Loss: 4.90 (which is 6.7% or 1.4 ATR below the current price).

Is ALVO a buy, sell or hold?

Alvotech has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALVO.

StrongBuy: 2
Buy: 0
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ALVO price?

Analysts Target Price	5.8	9.5%

Alvotech (ALVO) - Fundamental Data Overview as of 25 August 2026

Market Cap USD = 1.50b (1.50b USD * 1.0 USD.USD)
P/E Forward = 7.9114
P/S = 3.0293
Revenue TTM = 492.0m USD
EBIT TTM = -34.8m USD
EBITDA TTM = -1.43m USD
Long Term Debt = 1.26b USD (from longTermDebt, last fiscal year)
Short Term Debt = 53.8m USD (from shortTermDebt, last quarter)
Debt = 1.60b USD (from shortLongTermDebtTotal, last quarter) + Leases 147.7m
Net Debt = 1.46b USD (calculated: Debt 1.60b - CCE 142.8m)
Enterprise Value = 2.95b USD (1.50b + Debt 1.60b - CCE 142.8m)
Interest Coverage Ratio = -0.22 (Ebit TTM -34.8m / Interest Expense TTM 158.8m)
EV/FCF = -9.84x (Enterprise Value 2.95b / FCF TTM -300.2m)
FCF Yield = -10.16% (FCF TTM -300.2m / Enterprise Value 2.95b)
FCF Margin = -61.03% (FCF TTM -300.2m / Revenue TTM 492.0m)
Net Margin = -36.51% (Net Income TTM -179.6m / Revenue TTM 492.0m)
Gross Margin = 60.45% ((Revenue TTM 492.0m - Cost of Revenue TTM 194.6m) / Revenue TTM)
Gross Margin QoQ = 50.65% (prev 56.47%)
Tobins Q-Ratio = 1.86 (Enterprise Value 2.95b / Total Assets 1.59b)
Interest Expense / Debt = 9.93% (Interest Expense 158.8m / Debt 1.60b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -27.5m (EBIT -34.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.65 (Total Current Assets 545.0m / Total Current Liabilities 331.2m)
Debt / Equity = -8.35 (negative equity) (Debt 1.60b / totalStockholderEquity, last quarter -191.5m)
Debt / EBITDA = -1.02k (out of range, set to none) (Net Debt 1.46b / EBITDA -1.43m)
Debt / FCF = -4.85 (negative FCF - burning cash) (Net Debt 1.46b / FCF TTM -300.2m)
Total Stockholder Equity = -233.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.05% (Net Income -179.6m / Total Assets 1.59b)
RoE = 76.83% (negative equity) (Net Income TTM -179.6m / Total Stockholder Equity -233.8m)
RoCE = -3.38% (EBIT -34.8m / Capital Employed (Equity -233.8m + L.T.Debt 1.26b))
RoIC = -2.14% (negative operating profit) (NOPAT -27.5m / Invested Capital 1.29b)
WACC = 8.04% (E(1.50b)/V(3.10b) * Re(8.25%) + D(1.60b)/V(3.10b) * Rd(9.93%) * (1-Tc(0.21)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.40 | Cagr: 13.79%
[DCF] Fair Price = unknown (Cash Flow -300.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.22 | # QB: 0
Revenue Correlation: 84.21 | Revenue CAGR: 115.9% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=-40% | GrowthEPS=+103.0% | GrowthRev=+11.7%
EPS next Year (2027-12-31): EPS=0.21 | Chg30d=-9.33% | Revisions=+17% | GrowthEPS=+7044.3% | GrowthRev=+18.8%
[Analyst] Revisions Ratio: +0% (up=3, down=3)